EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study

Wen Lu iD, Alyssa Ziman, Charles Yin iD, Matthew T S Yan iD, Mrigender Singh Virk, Laura Dilly Stephens iD, Jay S Raval, Ghazala Radwi, Douglas Morrison, Gisela Marrero-Rivera iD, Jane Ly, Justin E Juskewitch und 16 weitere

Transfusion · 2026-06 · 66 (6) · 1086-1098

DOI: 10.1111/trf.70210 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Transfusion, online erschienen am 06.04.2026. Verfasst von Wen Lu und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Erythroblastosis, Fetal, Isoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐M antibodies were described as rarely eliciting hemolytic disease of the fetus and newborn (HDFN) in pregnancy. More recent literature, primarily from Asia, reports severe HDFN attributed to maternal anti‐M. The objective of this study is to determine if there is a difference in the frequency and/or severity of anti‐M HDFN among subjects who self‐report as Asian compared to non‐Asian.

Methods

Retrospective data were collected from 18 sites. Fetuses/neonates affected by HDFN were categorized as unaffected, mild, moderate, or severe based on clinical management and outcomes.

Results

Anti‐M was identified in 557 obstetric patients. Among 332 neonates with complete data for analysis, anti‐M was detected in isolation during the pregnancies of 210 (63.3%) neonates; 198 (94.3%) were unaffected by HDFN. The overall frequency of HDFN was 6.5% (2/31) in Asian patients and 5.6% (10/179) in non‐Asian patients. The frequency of severe HDFN was 6.5% (2/31) among Asian patients and 0.6% (1/179) among non‐Asian patients. Among non‐Asian patients, eight (4.5%) were mild and one (0.6%) was moderate. Of 63 pregnancies with anti‐M and ABO incompatibility, 6 (9.5%) were associated with mild HDFN and 57 (90.5%) were unaffected. Of 49 pregnancies with anti‐M and non‐ABO antibody(s), 6 (12.2%) were associated with mild HDFN and 43 (87.8%) were unaffected. One case (10.0%) of HDFN (mild) occurred in the presence of anti‐M, additional antibody(s), and ABO incompatibility.

Conclusion

In this study, severe anti‐M HDFN was rare in non‐Asian subjects. There is a signal that Asian patients are at greater risk for severe anti‐M HDFN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythroblastosis, FetalIsoantibodiesHumansFemalePregnancyRetrospective StudiesInfant, NewbornAdultAsian PeopleSelf Report

Stichwörter der Autor:innen

HDFNantenatal antibody screenanti‐M

Substanzen

Isoantibodies

Autor:innen und Institutionen

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Wing-Kwai and Alice Lee-Tsing Chung Transfusion Service, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, California, Los Angeles, USA.
  • Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Canadian Blood Services, Vancouver, British Columbia, Canada.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Fraser Health Authority, New Westminster, British Columbia, Canada.

ORCID-Profile: Wen Lu, Charles Yin, Matthew T S Yan, Laura Dilly Stephens, Gisela Marrero-Rivera, Rida A Hasan, Gwen Clarke, Sara Bakhtary, Maha Badawi

Zitieren

APA

Lu, W., Ziman, A., Yin, C., Yan, M. T. S., Virk, M. S., Dilly Stephens, L., Raval, J. S., Radwi, G., Morrison, D., Marrero-Rivera, G., Ly, J., Juskewitch, J. E., Ikeda, K., Hasan, R. A., Hands, K., El Malti, S., Eichbaum, Q. G., Duncan, J., Covello, T., …, & Biomedical Excellence for Safer Transfusion Collaborative (2026). Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study. Transfusion, 66(6), 1086-1098. https://doi.org/10.1111/trf.70210

Vancouver

Lu W, Ziman A, Yin C, Yan MTS, Virk MS, Dilly Stephens L, et al. Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study. Transfusion. 2026;66(6):1086-1098. doi:10.1111/trf.70210

BibTeX
@article{Lu2026,
  author = {Lu, Wen and Ziman, Alyssa and Yin, Charles and Yan, Matthew T S and Virk, Mrigender Singh and Dilly Stephens, Laura and Raval, Jay S and Radwi, Ghazala and Morrison, Douglas and Marrero-Rivera, Gisela and Ly, Jane and Juskewitch, Justin E and Ikeda, Kazuhiko and Hasan, Rida A and Hands, Katie and El Malti, Salwa and Eichbaum, Quentin G and Duncan, Jennifer and Covello, Thomas and Clarke, Gwen and Chang, Shelley and Brancamp, Rachel L and Bakhtary, Sara and Badawi, Maha and Au, Nicholas and AlMozain, Nour and Shan, Hua and Biomedical Excellence for Safer Transfusion Collaborative, Biomedical Excellence for Safer Transfusion Collaborative},
  title = {Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {6},
  pages = {1086--1098},
  doi = {10.1111/trf.70210}
}
Kostenlos starten →